Safety and cost-effectiveness of selective histopathological examination of appendices and gallbladders
- Conditions
- Appendix, Appendectomy, Gallbladder, Cholecystectomy, Pathology, Histopathological examination, Selective, Routine.Appendix, Appendectomie, Galblaas, Cholecystectomie, Pathologie, Histopathologisch onderzoek, Selectief, Routinematig.
- Registration Number
- NL-OMON23801
- Lead Sponsor
- Academic Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 8924
Inclusion Criteria
Patients of all ages who are scheduled to undergo an appendectomy or cholecystectomy in the elective or non-elective setting.
Exclusion Criteria
Appendix:
- Primary indication for surgery: strong suspicion or proven malignancy in the appendix.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Number of patients per 1000 examined appendices/gallbladders with a neoplasm requiring additional therapy benefitting the patient that would have been unnoticed in the policy of selective histopathological examination.<br /><br>2. Costs of the policy with selective and with routine histopathological examination of the appendix/gallbladder.<br>
- Secondary Outcome Measures
Name Time Method 1. Incidence of malignancies in resected appendices and gallbladders.<br /><br>2. Incidence of unnoticed malignancies in resected appendices and gallbladders.<br /><br>3. Incidence of malignancies in resected appendices and gallbladders that subsequently require more extensive resection or other additional treatment.<br /><br>4. Clinical consequences of more extensive resection or other additional treatment in patients with a malignancy found at histopathological examination of the appendix or gall bladder.<br /><br>a. Remaining tumour tissue and/or positive lymph nodes in re-resection specimen<br /><br>b. Postoperative complications<br /><br><br /><br>These secondary outcomes will also be reported for other aberrant findings as parasite infections, endometriosis, granulomatosis and benign neoplasms.